Skip to main content
. 2022 Nov 15;37(1):61–71. doi: 10.1038/s41375-022-01746-3

Fig. 5. Azacitidine combined with venetoclax improves survival in KMT2A-rearranged infant acute lymphoblastic leukemia xenografts.

Fig. 5

Kaplan–Meier survival curves of leukemia-bearing mice treated with 2.5 mg/kg azacitidine once daily for five days, 100 mg/kg venetoclax once daily for 21 days, simultaneous administration of 2.5 mg/kg azacitidine once daily for five days in combination with 100 mg/kg venetoclax once daily for 21 days, sequential administration of 2.5 mg/kg azacitidine once daily for five days followed by 100 mg/kg venetoclax once daily for 21 days, and vehicle control (n = 9–10 mice/group). Two xenograft models were used: LR-iALL2 and PER-785. Treatment commenced at (A) low disease burden when the percentage of human CD19+ CD45+ cells reached 1% in the bone marrow and (B) high disease burden when the percentage of human CD19+ CD45+ cells reached 1% in the peripheral blood. The gray shaded areas indicate the treatment periods, with the first dotted line representing the start of treatment for all cohorts and the last dotted line representing the end of treatment for sequential administration cohort. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.